International Myeloma Society Annual Meeting | Conference

Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma

September 28th 2023

Use of the novel T-charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T cells within 2 days was successful in producing rapid and robust in vivo expansion, as well as long-term T-cell persistence in patients with relapsed/refractory multiple myeloma, according to a correlative analysis of data from an ongoing phase 1 trial presented at the 2023 IMS Annual Meeting.

Systemic Review Sheds Light on Efficacy of Bispecific Antibodies in Extramedullary R/R Multiple Myeloma

September 28th 2023

Overall response rates with bispecific antibody monotherapy in patients with extramedullary relapsed/refractory multiple myeloma were lower than ORRs observed across all patients with relapsed/refractory multiple myeloma included in a systematic review evaluating the efficacy of this class of agents in this difficult-to-treat population.

Physical Activity Improves Performance, Frailty Scores, and PROs in Multiple Myeloma

September 28th 2023

Exercises such as resistance training and walking were safe and effective interventions that were associated with improved frailty scores in patients with multiple myeloma receiving systemic treatment.

Dr Beksac on OS Data From the OPTIMISMM Trial in Relapsed/Refractory Multiple Myeloma

September 28th 2023

Meral Beksac, MD, discusses overall survival data from the phase 3 OPTIMISMM trial in relapsed/refractory multiple myeloma.

Dr Leypoldt on the Use of Isa-KRd in Newly Diagnosed, High-Risk Multiple Myeloma

September 28th 2023

Lisa Leypoldt, MD, discusses findings from the phase 2 GMMG-CONCEPT trial in patients with multiple myeloma.

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

September 27th 2023

Treatment with the combination of isatuximab, carfilzomib, lenalidomide, and dexamethasone generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.

Cilta-cel Induces Favorable MRD Negativity Rates in Heavily Pretreated Myeloma After Prior BCMA-Directed Therapy

August 28th 2022

Ciltacabtagene autoleucel elicited high rates of minimal residual disease negativity in patients with heavily pretreated multiple myeloma who received prior treatment with a BCMA-targeted therapy.

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines of Therapy

August 28th 2022

Ciltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Dr. Cohen on the Efficacy of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

August 28th 2022

Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Dr. Raje on the Utilization of bb21217 in Relapsed/ Refractory Multiple Myeloma

August 28th 2022

Noopur Raje, MD, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.

Biallelic Deletion of TNFRSF17 Associated With Resistance to BCMA-Targeting Therapies In Myeloma

August 28th 2022

Identifying BCMA expression, copy number variation, and point mutations can have important therapeutic implications for patients receiving BCMA-targeting CAR T-cell therapy or T-cell engagers for multiple myeloma.

Daratumumab Plus RVd Improves Clinical Outcomes in Transplant-Eligible, Newly Diagnosed Multiple Myeloma

August 28th 2022

The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and consolidation treatment and lenalidomide maintenance therapy (D-RVd/D-R) resulted in high minimal residual disease rates and prolonged progression-free survival in patients with transplant-eligible, newly diagnosed multiple myeloma.

Busulfan/Melphalan Prior to ASCT Fails to Elicit PFS Benefit in Newly Diagnosed Myeloma

August 28th 2022

High-dose busulfan plus melphalan failed to generate a progression-free survival benefit vs melphalan for autologous stem cell transplant conditioning in patients with newly diagnosed multiple myeloma after induction therapy.

Bispecific Antibody ABBV-383 Looks to Fill Unmet Need in Heavily Pretreated Multiple Myeloma

August 28th 2022

Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma.

Relapse Following CAR T-cell Therapy Linked to Poor OS in Relapsed/Refractory Myeloma

August 27th 2022

Relapse following treatment with BCMA-directed CAR T-cell therapy was associated with poor survival outcomes in patients with relapsed/refractory multiple myeloma.

Isatuximab Plus Pomalidomide/Dexamethasone Maintains OS Benefit in R/R Myeloma

August 27th 2022

The addition of isatuximab to pomalidomide and low-dose dexamethasone continued to demonstrate improved overall survival in patients with relapsed/refractory multiple myeloma.

Isatuximab Plus Kd Demonstrates Deep Responses in Relapsed Multiple Myeloma

August 27th 2022

The addition of isatuximab to carfilzomib and dexamethasone elicited a clinically meaningful improvement in depth of response in patients with relapsed multiple myeloma.

REGN5458 Elicits Promising Responses, Safety in Relapsed/Refractory Myeloma

August 27th 2022

REGN5458 produced durable responses with low rates of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.

Multiple Myeloma Armamentarium Is Set to Explode as Novel Agents Show Encouraging Early Data

August 27th 2022

Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.

Dr. Richardson on Isatuximab Plus Pomalidomide/Dexamethasone in R/R Myeloma

August 27th 2022

Paul G. Richardson, MD, discusses the overall survival benefit displayed by isatuximab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.